BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bone Medical Ltd Announces Paul Hopper Appointed As Chairman Of The Board


10/19/2005 5:09:22 PM

Bone Medical Limited (ASX: BNE) (Bone Medical) has today announced that Paul Hopper has been appointed as Chairman of the Board effective 1st July 2005.

The appointment follows the intention of the Board to follow good governance practice to have separate CEO and Chairman roles.

Michael Redman, the current CEO and Chairman, will continue in his role as CEO and as a director of the Company.

"Bone Medical's decision to have both the CEO and Chairman based in the USA is a strategic move in line with the Company's international focus in terms of capital, likely collaborators and early adopters of Bone Medical's pipeline of therapies," said CEO Mr Michael Redman. "Our recent board changes, including Mr Hopper’s appointment as Chairman, will greatly enhance our efforts to expand our operations into the USA."

In April of 2005, the Company announced the addition of Wayne Fritzsche, who resides in Florida, to the Board. The Board reflects the international nature of the Company with half of the Board membership now comprised of members based in the USA, with two based in Australia (Perth and Sydney) and one situated in the United Kingdom.

Mr Hopper is an Australian based in San Diego, USA. He has 25 years' experience in public company markets in both countries, primarily in the healthcare and biotechnology sectors. His experience in Australia includes Managing Director of Alpha Healthcare Limited, which he co-founded in 1988, and ran until 1999. He is also the former Chief Executive Officer of Australian Cancer Technology Limited (now Avantogen Limited).

Mr Hopper’s current international experience includes Chairman of Innovate Oncology, Inc, a US listed biotechnology company, CEO of Evolve Oncology, Inc, a Director with Biodevelop Inc, and consultant to various other international biotechnology companies.

"Australia remains important to Bone Medical and we will continue to take advantage of the exceptional research and science here. We must also think of where our future lies and where our needs will be and it's on the regulatory, capital and commercial aspects that our US base will provide the most value", said Mr Redman.

Both the CEO and Chairman will visit Australia on a regular basis.

Bone Medical is currently conducting a Phase I Perthoxal oral parathyroid hormone clinical trial at St Vincent’s Hospital Clinical Trial Centre in Sydney and has additional R&D collaborations with the Institute for Bone & Joint Research in Sydney and the Institute for Molecular Biosciences in Brisbane.

For more information about Bone Medical Limited, please contact:

John Fitzgerald

Chief Operating Officer

+61 8 9355 5123

www.bonemedical.com

For media enquiries:

Rebecca Christie

Buchan Consulting

(02) 9237 2800

rchristie@bcg.com.au

About Bone Medical Limited

Bone Medical Limited is an international biopharmaceutical development company positioned to exploit the growing market in the treatment of bone disease particularly in osteoporosis and arthritis. Bone has a portfolio of biopharmaceutical development projects for the treatment of bone disease including,

Osteoporosis

Capsitonin oral calcitonin Perthoxal oral parathyroid hormone bone cell regulators BN005/BN008 Arthritis

TNF regulators BN006 joint protection & collagen tolerance BN007



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES